Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TtbioROCO:6493 -5.15%60 EBITDA Margin % is 1.20% as of Dec. 2025, which is 94% below its 10-year median of 20.36. GuruFocus rates ROCO:6493 with a GF Score™ of 60/100 and a GF Value™ of NT$19.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Ttbio ranks worse than 54.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ttbio's EBITDA for the
six
months ended in Dec. 2025 was NT$2.2 Mil. Ttbio's Revenue for the
six
months ended in Dec. 2025 was NT$186.0 Mil. Therefore, Ttbio's EBITDA margin for the quarter that ended in Dec. 2025 was 1.20%.
Ttbio (ROCO:6493) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ttbio EBITDA Margin % Related Terms
Ttbio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ttbio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6493 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Ttbio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ttbio EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ttbio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ttbio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ttbio (ROCO:6493) has a EBITDA Margin % of 1.20% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ttbio and its competitors. This is 94% below median its historical median of 20.36. Over the past decade, Ttbio's EBITDA Margin % has ranged from 5.11 to 47.44. According to the industry distribution chart, Ttbio ranks #446 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 54.7%.
Is Ttbio's EBITDA Margin % too high?
Ttbio's current EBITDA Margin % of 1.20% is 94% below median its 10-year median of 20.36. Over the past 10 years, this metric has ranged from a low of 5.11 to a high of 47.44. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Ttbio's value of 1.20% is 83.9% below this industry median. Based on the distribution chart, Ttbio ranks #446 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ttbio has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ttbio's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ttbio ranks #446 out of 816 companies for EBITDA Margin %. This places Ttbio in the lower half of its industry. The industry median EBITDA Margin % is 7.46. Ttbio's value of 1.20% is 83.9% below this benchmark. Historically, Ttbio's own EBITDA Margin % has ranged from 5.11 to 47.44 over the past decade. While the company's 10-year median is 20.36 vs. the industry median of 7.46, Ttbio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ttbio's current EBITDA Margin % of 1.20% is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ttbio and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ttbio's current EBITDA Margin % is 1.20%, which is 94% below median its own 10-year median of 20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ttbio stock overvalued right now?
Based on GuruFocus' analysis, Ttbio (ROCO:6493) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$19.62, compared to a current price of NT$48.85 — trading 149% above its estimated fair value. The current EBITDA Margin % is 1.20%, which is 94% below median its 10-year median of 20.36 and 83.9% below the Medical Devices & Instruments industry median of 7.46. Ttbio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ttbio (ROCO:6493), the current EBITDA Margin % is 1.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ttbio (ROCO:6493) Overvalued in 2026?
Based on GuruFocus' analysis, Ttbio stock appears to be overvalued.
The current stock price of NT$48.85 is trading 149% above its estimated GF Value™ of NT$19.62.
GuruFocus considers Ttbio to be Significantly Overvalued.
Key valuation signals for ROCO:6493:
EBITDA Margin %: 1.20% (94% below median its 10-year median of 20.36)
GF Value™: NT$19.62 vs. price of NT$48.85 (149% above fair value)
Industry Position: 83.9% below the Medical Devices & Instruments median (#446 of 816)
No single metric tells the full story. See the ROCO:6493 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ttbio Corp is a Taiwan based company engaged in the manufacturing of dental products and accessories. Its products include High-Speed Handpiece Series, Low-Speed Handpiece Series, Dental Spare Parts, Service Rotor, and Maintenance Unit among others.
60GF Score
Get the complete analysis for ROCO:6493
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6493 has been successfully added to your 
